Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for treating gouty nephropathy

A technology of gouty nephropathy and drugs, applied in the field of drug application, can solve problems such as renal function damage

Pending Publication Date: 2022-02-22
CHANGZHOU HI TECH DISTRICT MULTIPLE DIMENSION IND TECH INST
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Existing uric acid-lowering drugs such as allopurinol have side effects such as bone marrow suppression, liver and kidney damage, and skin toxicity. Benzbromarone can cause urate crystals to deposit in the urinary tract, causing renal colic and renal dysfunction; surgical treatment and Kidney dialysis is traumatic treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating gouty nephropathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Rats were fed with yeast feed and gavaged with uricase inhibitor potassium oxonate potassium for 60 days to establish a model. It was checked that the serum uric acid was stable above 300umol / L as a qualified model animal. The unqualified animals were eliminated and the uric acid level met the requirements. The rats were randomly divided into 6 groups, which were solvent control group (normal saline 2ml / kg), model control group (oxonate potassium 1.5g / kg), positive control group (allopurinol 40mg / kg) , L-carnitine low-dose group (150mg / kg), L-carnitine middle-dose group (300mg / kg) and L-carnitine high-dose group (600mg / kg), the number of animals in each group is 12. Continuous medication for 4 weeks. The metabolic cage collected 24-hour urine on the last day to detect the urine protein content. After the last administration, serum uric acid UA, creatinine, blood urea nitrogen BUN, reactive oxygen species ROS, and malondialdehyde MDA were detected. Kidneys were taken f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of levocarnitine or a derivative thereof in preparation of a medicine for treating gouty nephropathy, the levocarnitine derivative is selected from acetyl levocarnitine, propionyl levocarnitine, pharmaceutically acceptable salts of acetyl levocarnitine and propionyl levocarnitine and pharmaceutically acceptable salts of levocarnitine, and the medicine is administered in an oral administration form, an injection administration form or a local administration form.

Description

technical field [0001] The invention relates to the field of medicine application, in particular to the use of levocarnitine and its derivatives in the preparation of medicines for treating gouty nephropathy. Background technique [0002] Gouty nephropathy means that the concentration of urate in the blood increases to a supersaturated state, and urate crystals are deposited in the kidneys, causing pathological changes. The characteristic histology of a gouty kidney is urate crystals in the renal medulla or papilla, surrounded by round cells and giant cell reactions. The above-mentioned gouty renal manifestations are higher in the autopsy of gout patients, and are often accompanied by acute and chronic interstitial inflammatory changes, fibrosis, tubular atrophy, glomerulosclerosis and renal arteriosclerosis. [0003] In recent years, the incidence of gout has increased due to the increase in the intake of protein and purine-rich foods in our diet. Gout is more common in p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/205A61P19/06A61P13/12
CPCA61K31/205A61P19/06A61P13/12
Inventor 谢和兵吕伟红顾书华
Owner CHANGZHOU HI TECH DISTRICT MULTIPLE DIMENSION IND TECH INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com